Form 4: Natera Co-Founder Jonathan Sheena Sells Shares Under 10b5-1 Trading Plans

Jonathan Sheena, co-founder of Natera, Inc., executed multiple sales of common stock on October 1, 2024, under pre-arranged Rule 10b5-1 trading plans.

Summary

• On October 1, 2024, Jonathan Sheena, co-founder of Natera, Inc., sold shares of common stock.
• The sales were executed under two Rule 10b5-1 trading plans adopted on December 12, 2023, and March 13, 2023.
• A total of 2,694 shares were sold directly at prices ranging from $124.27 to $126.5050 per share.
• Additionally, 2,954 shares held by Caraluna 1 Trust and Caraluna 2 Trust for the benefit of Sheena's minor children were sold at prices ranging from $124.35 to $126.5050 per share.
• Following these transactions, Sheena directly owns 282,041 shares and indirectly owns 57,432 shares through each of the Caraluna trusts.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sales were conducted under pre-arranged trading plans, which mitigates potential negative sentiment. Overall, the sentiment is neutral.

Risks

• The sales by a company co-founder could be perceived negatively by investors, although they are conducted under pre-arranged trading plans.

Industry Context

Insider sales are a common occurrence in publicly traded companies, especially when executed under pre-arranged trading plans like Rule 10b5-1. These plans allow insiders to sell shares over a period of time, avoiding concerns about trading on material non-public information. Investors often monitor insider transactions for signals about a company's prospects, but Rule 10b5-1 sales are generally viewed as less informative than discretionary trades.

Comparison to Industry Standards

• It is difficult to compare this transaction to industry standards without knowing the specific details of Jonathan Sheena's overall holdings and financial situation.
• However, the use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and diagnostics sectors like Natera.
• Companies like Illumina, Exact Sciences, and Guardant Health also see regular insider trading activity, often through similar pre-arranged plans.

Stakeholder Impact

• The sales could have a minor impact on shareholder sentiment, although the use of Rule 10b5-1 plans suggests the transactions were pre-planned and not based on current inside information.

Key Dates